Schizophrenia Schizoaffective clinical trials

Explore recruiting schizophrenia schizoaffective clinical trials.

Recruiting schizophrenia schizoaffective studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Schizophrenia Schizoaffective trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for schizophrenia compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.

Austria, Germany, Spain, Italy

Therapeutic use (Phase IV) EU CTIS Study details

Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study.

Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)

Croatia

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major depressive disorder and bipolar depression compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.

Germany, Italy, Austria, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Schizophrenia Schizoaffective trials by city

Schizophrenia Schizoaffective in Toronto Schizophrenia Schizoaffective in Vancouver Schizophrenia Schizoaffective in Montreal Schizophrenia Schizoaffective in Calgary Schizophrenia Schizoaffective in Edmonton Schizophrenia Schizoaffective in Ottawa Schizophrenia Schizoaffective in Winnipeg Schizophrenia Schizoaffective in Quebec City Schizophrenia Schizoaffective in Hamilton Schizophrenia Schizoaffective in Kitchener Schizophrenia Schizoaffective in London Schizophrenia Schizoaffective in Halifax Schizophrenia Schizoaffective in New York Schizophrenia Schizoaffective in Los Angeles Schizophrenia Schizoaffective in Chicago Schizophrenia Schizoaffective in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease